CLONAZEPAM by Novartis is clinical pharmacology pharmacodynamics: the precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (gaba), the major inhibitory neurotransmitter in the central nervous system. Approved for panic disorder, with, without agoraphobia and 1 more indications. First approved in 1997.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Pharmacodynamics: The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the…
Worked on CLONAZEPAM at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Clonazepam 2 Mg Tablets
Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy
Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures